Literature DB >> 15502629

Congenital hypofibrinogenemia in pregnancy: report of two cases and review of the literature.

Evgenia Frenkel1, Chen Duksin, Arie Herman, Dan J Sherman.   

Abstract

Fibrinogen abnormalities have been implicated in many adverse pregnancy outcomes, mainly spontaneous abortion, placental abruption, and postpartum hemorrhage. Two new cases of congenital hypofibrinogenemia in pregnancy are reported detailing their obstetric course and management. The relevant obstetric and hematologic literature is reviewed, including previous case reports and studies concerning the mechanisms of pregnancy complications. Suggestions for treatment guidelines and management strategies are detailed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15502629     DOI: 10.1097/01.ogx.0000143774.04144.b9

Source DB:  PubMed          Journal:  Obstet Gynecol Surv        ISSN: 0029-7828            Impact factor:   2.347


  5 in total

Review 1.  Clinical Consequences and Molecular Bases of Low Fibrinogen Levels.

Authors:  Marguerite Neerman-Arbez; Alessandro Casini
Journal:  Int J Mol Sci       Date:  2018-01-08       Impact factor: 5.923

2.  Congenital hypofibrinogenemia in pregnancy: a report of 11 cases.

Authors:  He Cai; Meiying Liang; Jingjing Yang; Xiaohui Zhang
Journal:  Blood Coagul Fibrinolysis       Date:  2018-03       Impact factor: 1.276

Review 3.  Management of hemophagocytic lymphohistiocytosis in pregnancy: Case series study and literature review.

Authors:  Congcong Liu; Jinsong Gao; Juntao Liu
Journal:  J Obstet Gynaecol Res       Date:  2022-01-02       Impact factor: 1.697

4.  Hypofibrinogenemia and miscarriage: report of a first successful pregnancy under fibrinogen substitution and short review of the literature.

Authors:  Christoph Sucker; Christof Geisen; Ursula Schmitt; Bartosz Zawislak
Journal:  Arch Clin Cases       Date:  2022-09-26

Review 5.  Women With Congenital Hypofibrinogenemia/Afibrinogenemia: From Birth to Death.

Authors:  Yan Zhang; Xiaohang Zuo; Yue Teng
Journal:  Clin Appl Thromb Hemost       Date:  2020 Jan-Dec       Impact factor: 2.389

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.